title: Psychometric properties of the St George's Respiratory Questionnaire in patients with idiopathic pulmonary fibrosis.
abstract: The St George's Respiratory Questionnaire (SGRQ) has been used to measure health-related quality of life (HRQoL) in patients with idiopathic pulmonary fibrosis (IPF).This analysis evaluated the psychometric properties of the SGRQ using data from 428 patients with IPF who participated in a 12-month, randomised, placebo-controlled phase II trial of nintedanib.Internal consistency (Cronbach's α) was 0.91 for SGRQ total and >0.70 for domain scores. Test-retest reliability (intraclass correlation coefficients) was 0.77, 0.77, 0.69 and 0.66 for SGRQ total, activity, impact and symptoms scores, respectively. Construct validity of SGRQ total and domain scores was supported by weak to moderate cross-sectional correlations with the Medical Research Council dyspnoea scale (0.32-0.55), 6-min walk test distance (-0.25- -0.34), percentage predicted forced vital capacity (-0.11- -0.15) and measures of gas exchange (-0.26-0.03). There was some evidence that the SGRQ total score was sensitive to detecting change.The reliability, construct validity and responsiveness of the SGRQ in patients with IPF suggest that this is an acceptable measure of HRQoL in patients with IPF.
authors.affiliation: National Jewish Health, Denver, CO, USA swigrisj@njc.org.
authors.forename: Jeffrey J
authors.initials: JJ
authors.lastname: Swigris
authors.affiliation: Boehringer Ingelheim GmbH, Ingelheim am Rhein, Germany.
authors.forename: Dirk
authors.initials: D
authors.lastname: Esser
authors.affiliation: Evidera, Bethesda, MD, USA.
authors.forename: Hilary
authors.initials: H
authors.lastname: Wilson
authors.affiliation: Boehringer Ingelheim Pharmaceuticals, Inc., Ridgefield, CT, USA.
authors.forename: Craig S
authors.initials: CS
authors.lastname: Conoscenti
authors.affiliation: Boehringer Ingelheim GmbH & Co. KG, Ingelheim am Rhein, Germany.
authors.forename: Hendrik
authors.initials: H
authors.lastname: Schmidt
authors.affiliation: Boehringer Ingelheim GmbH & Co. KG, Ingelheim am Rhein, Germany.
authors.forename: Wibke
authors.initials: W
authors.lastname: Stansen
authors.affiliation: Evidera, Bethesda, MD, USA.
authors.forename: Nancy Kline
authors.initials: NK
authors.lastname: Leidy
authors.affiliation: National Jewish Health, Denver, CO, USA.
authors.forename: Kevin K
authors.initials: KK
authors.lastname: Brown
mesh_terms: D000368:Aged; D003430:Cross-Sectional Studies; D004311:Double-Blind Method; D005260:Female; D005858:Germany; D006801:Humans; D054990:Idiopathic Pulmonary Fibrosis / Q000188:drug therapy* / Q000503:physiopathology*; D007211:Indoles / Q000627:therapeutic use*; D008297:Male; D008875:Middle Aged; D000071066:Patient Reported Outcome Measures; D011594:Psychometrics; D011788:Quality of Life; D015203:Reproducibility of Results; D011795:Surveys and Questionnaires; D014797:Vital Capacity; D000070857:Walk Test
chemical_list: D007211:Indoles; C530716:nintedanib